2025 annuity sales creep closer to $500 billion, LIMRA reports
Total U.S. annuity sales increased 6% to $461.3 billion in 2025, according to preliminary results from LIMRA’s U.S. Individual Annuity Sales Survey, which represents 92% of the total U.S. annuity market.
Fourth quarter sales jumped 12% to $114.4 billion, representing the ninth consecutive quarter of $100+ billion in sales.
“Indexed products — registered index-linked and fixed indexed annuities — represented 45% of total sales in 2025, up from just 24% market share a decade ago. Expanded capacity, enhanced products, growing distribution and investor demand have propelled sales of these solutions,” said Bryan Hodgens, senior vice president and head of LIMRA research. “LIMRA is forecasting RILA and FIA sales to grow through 2028 and expand their market share of the total annuity market.”
LIMRA provided a sales breakdown by product category:
Fixed indexed annuities
Fourth quarter fixed indexed annuity (FIA) sales improved 8% year over year to $34.4 billion. In 2025 FIA sales were $128.2 billion, 1% higher than 2024 results. This is the fifth consecutive year of annual sales growth for the product line and sets a new sales record.
Registered index-linked annuities
Registered index-linked annuity (RILA) sales set new quarterly and annual sales records. In the fourth quarter of 2025, RILA sales were $22.2 billion, 24% higher than the prior year. In 2025, RILA sales increased 20% year over year to $79.6 billion, 10 times the sales recorded a decade ago for this product line and marks the 11th consecutive year of growth.
“LIMRA expects the RILA market will continue to expand as more carriers enter the space or introduce new products,” said Keith Golembiewski, assistant vice president and head of LIMRA Annuity Research. “LIMRA is projecting RILA sales to exceed $85 billion in 2026, and for this market to grow through 2028.”
Traditional variable annuities
Traditional variable annuity sales were $18 billion in the fourth quarter, up 8% from fourth quarter 2024. For the year, traditional VA sales improved 7% year over year to $65.2 billion.
Fixed-rate deferred
Although fourth quarter 2025 fixed-rate deferred annuity (FRD) sales declined 24% from the prior quarter, they increased 12% year over year to $32.8 billion. In 2025, FRD sales improved 5% year over year to $160.6 billion.
“In the third quarter of 2025, FRD sales were elevated as investors rushed to lock in rates before anticipated interest rate cuts. Though fourth quarter sales have normalized, FRD products continue, on average, to offer better rates than CDs and remain attractive to risk-adverse investors looking for higher protected investment growth,” noted Golembiewski. “LIMRA is forecasting 2026 FRD sales to fall below 2025 sales levels as short-duration appeal fades in conjunction with lower interest rates.”
Fixed indexed annuities
Fourth quarter fixed indexed annuity (FIA) sales improved 8% year over year to $34.4 billion. In 2025 FIA sales were $128.2 billion, 1% higher than 2024 results. This is the fifth consecutive year of annual sales growth for the product line and sets a new sales record.
Income annuities
Single premium immediate annuity (SPIA) sales increased 12% in the fourth quarter to $3.5 billion. For the year, SPIA sales ticked up 3% to $14 billion. Deferred income annuity (DIA) sales jumped 20% to $1.4 billion in the fourth quarter. DIA product sales fell 3% to $4.8 billion in 2025.
“Over the past five years, industry has done a remarkable job of expanding and enhancing the portfolio of annuity solutions to meet the needs of today’s investors,” said Hodgens. “We are in the middle of Peak65, when more than 4 million Americans are entering retirement each year, often with fewer protected lifetime income sources available. Our research suggests the demand for solutions that offer security — and peace of mind — has never been greater. This year, LIMRA has expanded its mission to help engage and educate financial professionals and consumers about the important role annuities can play in a holistic retirement plan to ensure lifetime financial security.”
Preliminary fourth quarter 2025 annuity industry estimates are based on monthly reporting. A summary of the results can be found in LIMRA’s Fact Tank.
The top 20 rankings of total, variable and fixed annuity carriers for 2025 will be available in mid-March, following the last of the earnings calls for the participating carriers, the release said.
LIMRA’s Retail Annuity Sales Survey represents 92% of the U.S. market. With more than 100 years of expertise, LIMRA conducts over 80 benchmark studies — producing nearly 500 reports annually — for our members and the industry.



SEC: Get-rich-quick influencer Tai Lopez was running a Ponzi scam
Lincoln reports strong life/annuity sales, executes with ‘discipline and focus’
Advisor News
- Advisors get a win as NJ Senate passes independent contractor bill
- Why federal retirement benefits are more complex than advisors realize
- Why timing the market is still a retirement mistake and what to do instead
- Business owners may be overlooking a key part of their financial picture
- How smart investments prepare clients for inflation
More Advisor NewsAnnuity News
- Best’s Special Report: U.S. Life/Annuity Industry Sees Bottom-Line Growth Despite 18% Decline in Total Income in First-Quarter 2026
- Globe Life Inc. (NYSE: GL) Records 52-Week High Thursday Morning
- Fortitude Re Completes $500 Million FABN Issuance
- Reframing retirement income for greater certainty
- Jackson Introduces Dow Jones Industrial Average Index Option, Flexible Premiums, Six-Year Rate Guarantee in Latest Registered Index-Linked Annuity Launch
More Annuity NewsHealth/Employee Benefits News
- AHA FILES AMICUS BRIEF IN CASE CHALLENGING HHS, CMS ON PROVIDER TAXES
- New Geriatrics and Gerontology Findings Reported from University of Pennsylvania (Health insurance, healthcare access, and their roles in the association between blood lead levels and epigenetic aging in United States adults): Aging Research – Geriatrics and Gerontology
- Investigators at Avalere Health Report New Data on Atopic Dermatitis (Tralokinumab as a cost-saving treatment option for adults and adolescents with moderate-to-severe atopic dermatitis enrolled in US health insurance plans: a budget impact …): Skin Diseases and Conditions – Atopic Dermatitis
- NATIONAL BRIEFS
NATIONAL BRIEFS
- Senate sends revenue-raising package taxing software, health plans to Newsom
More Health/Employee Benefits NewsLife Insurance News
- Maryland Heights man pleads guilty in murder-for-hire death of his mom
- AM Best Affirms Credit Ratings of Everlake Life Group Members
- Industry experts warn NAIC: Fix flawed IUL illustrations now
- InsuranceAUM.com Celebrates a Historic 5th Annual Insurance Investment Executives’ Meeting in Chicago, Honoring Outstanding Industry Leaders and Spotlighting Next Event in Austin
- Pacific Life Launches Income Horizon™ Collective Investment Trust Series, Transforming Lifetime Income into an Asset Class
More Life Insurance News